Form 4 for CPHI CHINA PHARMA HOLDINGS, INC.
Accepted 2023-10-19 00:00:00 ET · period of report 2023-09-29 · accession 0001013762-23-005114 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-19 | 2023-09-29 | CPHI | Li Zhilin | CEO, Interim CFO, Dir, 10% | A - Grant | $0.14 | +13.76M | 15.14M | +996% | +$1.93M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-29 | A | A | 13,757,063 | $0.14 | 15,138,063 | D | — | — | (F1) On September 29, 2023, the reporting person was granted 13,757,063 shares of Issuer's common stock pursuant to certain loan settlement agreement with the Company to settle a loan in the amount of $1,854,452.10 that the Company owed to the reporting person. (F2) After giving effect to the 1-for-10 reverse stock split on March 6, 2023, resulting 13,810,000 shares the reporting person previously owned being 1,381,000 shares. |